# Chromane Derivatives from Underground Parts of *Iris tenuifolia* and Their In Vitro Antimicrobial, Cytotoxicity and Antiproliferative Evaluation

Oldokh Otgon [1], Suvd Nadmid [2], Christian Paetz [3], Hans-Martin Dahse [4], Kerstin Voigt [4], Stefan Bartram [3], Wilhelm Boland [3] and Enkhmaa Dagvadorj [1,*]

[1] Department of Chemistry, School of Biomedicine, Mongolian National University of Medical Sciences, S. Zorig Street 3, Ulaanbaatar 14210, Mongolia; oldokh.o@mnums.edu.mn

[2] Department of Pharmaceutical Chemistry, School of Pharmacy, Mongolian National University of Medical Sciences, S. Zorig Street 3, Ulaanbaatar 14210, Mongolia; suvd.n@mnums.edu.mn

[3] Max Planck Institute for Chemical Ecology, Hans-Knoell-Strasse 8, D-07745 Jena, Germany; cpaetz@ice.mpg.de (C.P.); bartram@ice.mpg.de (S.B.); boland@ice.mpg.de (W.B.)

[4] Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (HKI), Adolf-Reichwein-Strasse 23, D-07745 Jena, Germany; hans-martin.dahse@leibniz-hki.de (H.-M.D.); kerstin.voigt@hki-jena.de (K.V.)

* Correspondence: enkhmaa.d@mnums.edu.mn; Tel.: +976-99084787

**Abstract:** Phytochemical investigation of the ethanol extract of underground parts of *Iris tenuifolia* Pall. afforded five new compounds; an unusual macrolide termed moniristenulide (**1**), 5-methoxy-6,7-methylenedioxy-4-*O*-2′-cycloflavan (**2**), 5,7,2′,3′-tetrahydroxyflavanone (**3**), 5-hydroxy-6,7-dimethoxyisoflavone-2′-*O*-β-D-glucopyranoside (**9**), 5,2′,3′-dihydroxy-6,7-dimethoxyisoflavone (**10**), along with seven known compounds (**4–8**, **11–12**). The structures of all purified compounds were established by analysis of 1D and 2D NMR spectroscopy and HR-ESI-MS. The antimicrobial activity of the compounds **1–3**, **5**, **9**, and **10** was investigated using the agar diffusion method against fungi, Gram-positive and Gram-negative bacteria. In consequence, new compound **3** was found to possess the highest antibacterial activity against *Enterococcus faecalis* VRE and *Mycobacterium vaccae*. Cell proliferation and cytotoxicity tests were also applied on all isolated compounds and plant crude extract in vitro with the result of potent inhibitory effect against leukemia cells. In particular, the newly discovered isoflavone **10** was active against both of the leukemia cells K-562 and THP-1 while **4–6** of the flavanone type compounds were active against only THP-1.

**Keywords:** *Iris tenuifolia*; Iridaceae; chromane; macrolide; flavonoids; antimicrobial; antiproliferative effect; cytotoxicity

## 1. Introduction

*Iris* is a genus of the family Iridaceae that consists of about 360 species of perennial herbs and sub shrubs. *Iris* species are widely distributed in the temperate northern hemisphere, including Euro-Asia, North Africa and North America [1]. Many members of the genus *Iris* have been used as traditional folk medicines for the treatment of various diseases, such as cancer, inflammation, bacterial and viral infections [2,3]. Previous phytochemical investigations on *Iris* plants have resulted in the isolation of a variety of secondary metabolites, which mainly include flavonoids, xanthones, terpenoids, steroids, quinones, stilbenes and simple phenolics. Moreover, the plant extracts and isolated compounds from these species were reported to have anti-inflammatory, antioxidant, antimicrobial, antitumor, antimutagenic, cytotoxic, immunomodulating, hepatoprotective, antiproliferative, estrogenic, cholinesterase inhibitory, cell proliferation stimulatory, antidiabetic and molluscicidal activities [1,4–7]. About 24 species are found in Mongolia. Specifically, *Iris tenuifolia* Pall., a characteristic plant of desert grasslands of Mongolia, is distributed in Mongol-Altai,

Eastern Mongolia, Eastern Gobi and Gobi-Altai province [8,9]. The roots and rhizomes of *I. tenuifolia* are all commonly used as a traditional Mongolian medicine for treatment of kidney disorder. A root decoction of the plant has been used as a folk remedy for hypertension caused by adrenal gland diseases, ureter stones to relief renal colic and chronic nephritic [10]. This study deals with the isolation and structural elucidation of the new type of macrolide, named moniristenulide (**1**) and four previously unprecedented compounds: 5-methoxy-6,7-methylenedioxy-4-*O*-2′-cycloflavan (**2**), 5,7,2′,3′-tetrahydroxyflavanone (**3**), 5-hydroxy-6,7-dimethoxyisoflavone-2′-*O*-β-D-glucopyranoside (**9**), 5,2′,3′-trihydroxy-6,7-dimethoxyisoflavone (**10**), together with seven known compounds (Figure 1): four flavanone (**4**, **5**, **6**, **7**), one isoflavone (**8**), one flavonol (**11**), and one sterol (**12**). In addition, we aimed to evaluate the effectiveness and potency of these natural compounds using antimicrobial, cell proliferation and cytotoxicity assays.



**Figure 1.** The structures of compounds **1–12**.

## 2. Results and Discussion

### 2.1. Structure Elucidation

The ethanol extracts from the underground parts of *I. tenuifolia* were subjected to repeated column chromatography followed by crystallizations leading to the isolation of five unprecedented chromane derivatives.

Compound **1** was isolated as white crystal. HR-ESI-MS showed an ion peak at *m/z* 453.1409 [M + H]+ corresponding to a molecular formula of $C_{21}H_{24}O_{11}$. Its ^{1}H NMR spectrum acquired in DMSO-$d_6$ (Table 1) showed resonances for meta-coupled aromatic protons at $\delta_H$ 6.14 (1H, *J* = 2.0 Hz) and $\delta_H$ 5.95 (1H, *J* = 2.0 Hz), two olefinic protons at $\delta_H$ 6.94 and $\delta_H$ 5.75, methylene signals between $\delta_H$ 3.21–1.81 and number of oxygenated protons between $\delta_H$ 5.50–3.08 corresponding to hydroxy groups as well as oxymethines. The presence of a 2,5,7-trisubstituted chromane-4-one was identified by analysis of HMBC correlations observed for the meta-coupled aromatic doublets H-6 and H-8 as well as methylene signals H-2 and H-3 (Figure 2a). Moreover, the ^{1}H NMR spectrum exhibited a signal of one chelated hydroxyl group ($\delta_H$ 12.04), which is characteristic downfield shift of a hydroxyl group at C-5 and a carbonyl group at C-4. In addition, the presence of a hydroxyl group at C-5 was supported by HMBC correlations from 5-OH ($\delta_H$ 12.04) to C-5 ($\delta_C$ 163.1), C-6 ($\delta_C$ 97.3) and C-10 ($\delta_C$ 103.4). HSQC, HMBC, and COSY data clearly revealed the existence of a glucose residue. Further analysis of the spin-spin couplings (*J* = 7.7 Hz)

allowed the identification of *β*-D-glucose. Connectivity of sugar moiety with chromane ring was deduced through HMBC correlation from the anomeric proton H-1″ ($\delta_H$ 5.09) to C-7 ($\delta_C$ 164.1) of aglycon. A remaining spin system observed on the COSY spectrum comprised a series of protons H-2′–H-6′. HMBC correlations from olefinic protons H-2′ and H-3′ to a carbonyl carbon at $\delta_C$ 164.8 (C-1′) allowed for establishing 6-hydroxy-2-hexenoic acid residue. *Trans* configuration of the double bond has been identified by a large coupling constant of 15.6 Hz. This substructure has been linked to the aglycon on position C-2 by HMBC correlations from the H-5′ and H-6′ to a carbon at $\delta_C$ 76.9 (C-2) and in turn H-3 to a carbon at $\delta_C$ 70.9 (C-6′). Interestingly, a macrolide structure was established via ester linkage between sugar residue and carbonyl carbon of hexenoic acid by strong heteronuclear long-range correlation from H-6″ to C-1′. ROESY correlations between diastereotopic H-3$_{eq}$ (*β*) and H-2 and H-6′ indicated that these protons are on the same side of the chromane ring. In turn, H-3$_{ax}$ showed ROESY correlation to 6′-OH. From the above findings, relative configuration at C-2 and C-6′ has been established as *β*-configured (Figure 2b). The absolute configuration at C-2 was found to be S as it showed positive and negative Cotton effects at 305 and 287 nm, respectively in the circular dichroism (CD) spectrum (Figure S9, Supplementary Materials) [11,12]. Thus, the structure of compound **1** was established as a new type of macrolide, named moniristenulide, as shown in Figure 1.

**Table 1.** 1D and 2D NMR (500 MHz) data of moniristenulide (**1**) in DMSO-$d_6$ ($\delta$ in ppm, *J* in Hz).

| Position | $\delta_H$ | $\delta_C$ | HMBC | $^1$H-$^1$H COSY | ROESY |
|---|---|---|---|---|---|
| 2 | 4.58 brd (13.4) | 76.9 | C-4, C-3 | H-3$_{ax}$, H-3$_{eq}$, H-6′ | H-3$_{eq}$, H-3′, H-4$_b$′, H-6′ |
| 3$_{ax}$ | 3.21 m | 38.5 | C-4, C-6′ | H-2, H-3$_{eq}$ | H-3$_{eq}$, 6′-OH |
| 3$_{eq}$ | 2.40 m | | C-4, C-10 | H-2, H-3$_{ax}$ | H-2, H-6′, H-3$_{ax}$ |
| 4 | - | 198.5 | - | - | - |
| 5 | - | 163.1 | - | - | - |
| 6 | 5.95 d (2.0) | 97.3 | C-7, C-8, C-10 | - | - |
| 7 | - | 164.1 | - | - | - |
| 8 | 6.14 d (2.0) | 94.7 | C-4, C-6, C-7, C-10 | - | H-3′, H-1″ |
| 9 | - | 162.4 | - | - | - |
| 10 | - | 103.4 | - | - | - |
| 1′ | - | 164.8 | - | - | - |
| 2′ | 5.75 d (15.6) | 120.2 | C-1′, C-3′, C-4′ | H-3′, H-4′$_{ab}$ | H-3′ |
| 3′ | 6.94 m | 150.1 | C-1′, C-2′, C-4′, C-5′ | H-2′, H-4′$_{ab}$ | H-2, H-8, H-5′$_b$ |
| 4′$_a$ | 2.41 m | 25.3 | - | H-3′, H-4′$_b$ | - |
| 4′$_b$ | 2.07 m | | C-2′, C-3′ C-5′, C-6′ | H-3′, H-5′$_b$, H-4′$_a$ | - |
| 5′$_a$ | 2.01 m | 29.7 | C-2, C-3′, C-4′ | H-6′, H-4′$_a$, H-5′$_b$ | - |
| 5′$_b$ | 1.81 m | | C-3′, C-4′, C-6′ | H-6′, H-5′$_a$ | - |
| 6′ | 3.54 m | 70.9 | C-2 | H-2, 6′-OH, H-5′$_{ab}$ | H-2, H-3$_{eq}$, H-4′$_b$, 6′-OH |
| 1″ | 5.09 d (7.7) | 98.0 | C-7, C-5″ | H-2″ | H-8, H-3″, H-5″ |
| 2″ | 3.27 overlap | 72.8 | C-1″, C-3″, C-4″ | H-1″, 2″-OH | - |
| 3″ | 3.32 overlap | 76.3 | C-2″ | H-4″, 3″-OH | - |
| 4″ | 3.08 m | 70.2 | C-3″, C-6″ | H-5″, 4″-OH | - |
| 5″ | 3.71 t (10.4, 1.2) | 74.4 | C-1″, C-3″, C-4″, C-6″ | H-4″, H-6″$_a$, H-6″$_b$ | H-1″, H-3″, H-6″$_a$ |
| 6″$_a$ | 4.36 brd (11.5) | 63.2 | C-1′, C-1″, C-5″ | H-5″, H-6″$_b$ | H-2, H-5″, H-6″$_b$, 4″-OH |
| 6″$_b$ | 4.06 brd (10.9) | | C-1′, C-5″ | H-5″, H-6″$_a$ | - |
| 5-OH | 12.04 s | - | C-4, C-5, C-6, C-10 | - | - |
| 6′-OH | 5.14 d (5.9) | - | C-2, C-5′, C-6′ | H-6′ | H-3$_{ax}$ |
| 2″-OH | 5.50 d (5.1) | - | C-1″, C-2″, C-3″ | H-2″ | H-2″ |
| 3″-OH | 5.25 d (5.1) | - | C-2″, C-3″, C-4″ | H-3″ | - |
| 4″-OH | 5.36 d (5.1) | - | C-3″, C-4″, C-5″ | H-4″ | H-4″, H-6″$_a$ |

**Figure 2.** (a) ^{1}H-^{1}H COSY (—) and key HMBC (→) correlations of moniristenulide (**1**); (b) ROESY correlation (dashed arrow) establishing relative configuration of **1**.

Compound **2** was isolated as colorless crystal. Its HR-ESI-MS at *m/z* 299.0919 [M + H]$^+$ suggested a molecular formula of $C_{17}H_{14}O_5$. Its ^{1}H NMR spectrum showed resonances for five aromatic protons at $\delta_H$ 7.33 (1H, dd, *J* = 1.7, 7.5 Hz), 7.20 (1H, ddd, *J* = 1.7, 7.4, 7.4 Hz), 6.89 (1H, overlap.), 6.87 (1H, overlap.), 6.08 (1H, s), two signals of oxygenated methylene at $\delta_H$ 5.81 and $\delta_H$ 5.76 (each 1H, d, *J* = 1.5 Hz), two oxygenated methine protons at $\delta_H$ 5.64 (1H, dd, *J* = 2.8, 4.4 Hz) and 5.25 (1H, dd, *J* = 2.6, 4.4 Hz), two signals of diastereotopic methylene protons at $\delta_H$ 2.27 (1H, dt, *J* = 2.8, 13.8 Hz) and 2.15 (1H, dt, *J* = 2.8, 13.8 Hz) and one methoxy singlet at $\delta_H$ 4.09 (3H, s). Analysis of ^{13}C NMR spectrum combined with HSQC allowed for identifying the existence of 17 carbon atoms, including 12 sp$^2$ carbons, two methylene carbons at $\delta_C$ 26.5 and 100.8, two methine carbons at $\delta_C$ 67.5 and 62.4, and one methoxy group at $\delta_C$ 60.1 (Table 2). The COSY correlations of four aromatic protons at $\delta_H$ 7.33, 7.20, 6.89 and 6.87 (H-3′–H-6′) along with the respective HMBC correlations confirmed a presence of disubstituted aromatic B-ring, while the remaining sharp singlet at $\delta_H$ 6.08 (H-8) described a typical penta-substituted aromatic A-ring. Furthermore, the COSY experiment showed another spin system from H-2 to H-4 and indicated a CH-CH$_2$-CH sequence. Additionally, the key HMBC correlation from H-6′ ($\delta_H$ 7.33) to C-2 ($\delta_C$ 67.5) revealed the flavan (2-phenylchromane) skeleton (Figure 3). The HMBC correlation from methine H-4 ($\delta_H$ 5.64) to C-2′ ($\delta_C$ 153.6) and their chemical shift indicated their linkage through an oxygen bridge. All these data deduced that compound **2** has a 4-*O*-2′-cycloflavan as a partial structure. The remaining two doublet signals at $\delta_H$ 5.81 and 5.76 had one bond correlation to a carbon atom at $\delta_C$ 100.8, which were assigned as a methylenedioxy group. These methylenedioxy doublet was connected to a flavan core by key HMBC correlations to C-6 and C-7. The location of methoxy group ($\delta_H$ 4.09) at C-5 was suggested by HMBC correlations. On the basis of the above evidence, the planar structure of compound **2** was elucidated as 5-methoxy-6,7-methylenedioxy-4-*O*-2′-cycloflavan and considered as an unprecedented natural product. This spectroscopic data of compound **2** is somewhat similar to the literature values for the known 4-*O*-2′-cycloflavan core structures, possessing a different substitution pattern in aromatic A- and B-rings [7,13,14].

Compound **3** was isolated as yellow solid. It showed a molecular ion peak at *m/z* 289.0714 [M + H]$^+$ ascribable to a molecular formula of $C_{15}H_{12}O_6$. The ^{1}H NMR spectrum showed resonances for five aromatic proton signals at $\delta_H$ 5.88 (1H, d, *J* = 2.0 Hz), 5.90 (1H, d, *J* = 2.0 Hz), 6.69 (1H, t, *J* = 7.8 Hz), 6.79 (1H, dd, *J* = 1.4, 7.9 Hz), 6.88 (1H, dd, *J* = 1.4, 7.8 Hz), three aliphatic protons at $\delta_H$ 5.70 (1H, dd, *J* = 2.9, 12.9 Hz), 3.17 (1H, dd, *J* = 12.9, 17.0 Hz), and 2.69 (1H, dd, *J* = 3.0, 17.0 Hz), and four oxygenated protons at $\delta_H$ 12.12, 10.79, 9.51, and 8.71, one of which was appeared as a chelated hydroxyl group. The ^{13}C NMR spectrum contained signals from 15 carbon atoms, which were with the full agreement of HR-MS (Table 2). Partial structure 2,5,7-trisubstituted chromane-4-one was deduced from the analysis of protons H-2 and H-3, which were existing in an AMX spin system (Figure 3). In addition, hydroxyl groups at C-5 and C-7 were supported by HMBC correlations from 5-OH ($\delta_H$ 12.12) to C-5 ($\delta_C$ 163.5), C-6 ($\delta_C$ 95.8) and C-10 ($\delta_C$ 101.7) and from 7-OH to C-6 ($\delta_C$ 95.8) and C-7 ($\delta_C$ 166.6). In addition, a COSY correlation of three

aromatic protons at $\delta_H$ 6.69, 6.79, 6.88 along with HMBC correlations from proton H-4′ ($\delta_H$ 6.79) to C-2′ ($\delta_C$ 142.6), C-3′ ($\delta_C$ 145.2) and from proton H-6′ ($\delta_H$ 6.88) to C-2 ($\delta_C$ 74.0), C-2′ ($\delta_C$ 142.6), and C-4′ ($\delta_C$ 115.2) revealed a presence of a 2,3-dihydroxyphenyl moiety (ring-B) and altogether confirmed the flavanone structure. This was further supported by key long-range heteronuclear correlations from the methine proton H-2 ($\delta_H$ 5.70) to C-2′ ($\delta_C$ 142.6). The position of the remaining two hydroxyl protons at $\delta_H$ 9.51 and 8.71 were assigned to C-3′ and C-2′ respectively, due to observed HMBC correlations. Spectral data of **3** possess close similarity to those for the known compounds **5** and **6** [15]. The only difference was observed for the substitution on C-7, where methoxy group in **6** and methylenedioxy group in **5,** while it was replaced by hydroxy group in **3**. This was supported by HMBC correlations from 7-OH to C-6, C-7, and C-8 in **3** (Figure 3).

**Table 2.** ¹H NMR (500 MHz) and ¹³C NMR (125 MHz) data of compounds **2**, **3**, **9**, and **10** ($\delta$ in ppm, *J* in Hz).

| Position | 2 * | | 3 ** | | 9 ** | | 10 * | |
|---|---|---|---|---|---|---|---|---|
| | $\delta_H$ | $\delta_C$ | $\delta_H$ | $\delta_C$ | $\delta_H$ | $\delta_C$ | $\delta_H$ | $\delta_C$ |
| 2 | 5.25 dd (2.6, 4.4) | 67.5 | 5.70 dd (2.9, 12.9) | 74.0 | 8.44 s | 157.1 | 8.16 s | 156.3 |
| 3 | 2.27 dt (2.8, 13.8) | 26.5 | 3.17 dd (12.9, 17.0) | 41.1 | - | 118.9 | - | 122.8 |
| | 2.15 dt (2.8, 13.8) | | 2.69 dd (3.0, 17.0) | | - | | - | |
| 4 | 5.64 dd (2.8, 4.4) | 62.4 | - | 196.4 | - | 180.5 | - | 182.4 |
| 5 | - | 141.1 | - | 163.5 | - | 156.8 | - | 158.1 |
| 6 | - | 129.9 | 5.88 d (2.0) | 95.8 | - | 128.3 | - | 128.9 |
| 7 | - | 150.5 | - | 166.6 | - | 158.3 | - | 159.7 |
| 8 | 6.08 s | 92.5 | 5.90 d (2.0) | 94.9 | 6.64 s | 96.1 | 6.54 s | 96.9 |
| 9 | - | 148.9 | - | 163.2 | - | 149.2 | - | 149.7 |
| 10 | - | 106.1 | - | 101.7 | - | 104.8 | - | 104.9 |
| 1′ | - | 121.3 | - | 125.5 | - | 120.0 | - | 119.8 |
| 2′ | - | 153.6 | - | 142.6 | - | 155.1 | - | 147.7 |
| 3′ | 6.87 overlap | 117.2 | - | 145.2 | 7.27 d (8.2) | 115.5 | - | 142.6 |
| 4′ | 7.20 ddd (1.7, 7.4, 7.4) | 130.6 | 6.79 dd (1.4, 7.9) | 115.2 | 7.37 overlap | 129.7 | 7.03 dd (1.3, 7.9) | 115.6 |
| 5′ | 6.89 overlap | 120.4 | 6.69 t (7.8) | 119.1 | 7.09 t (7.5) | 121.5 | 6.92 t (7.9) | 122.2 |
| 6′ | 7.33 dd (1.7, 7.5) | 130.9 | 6.88 dd (1.4, 7.8) | 117.1 | 7.35 overlap | 131.9 | 6.71 dd (1.5, 7.8) | 120.3 |
| 5-OCH₃ | 4.09 s (3H) | 60.1 | - | - | - | - | - | - |
| -OCH₂O- | 5.76 d (1.5) 5.81 d (1.5) | 100.8 | - | - | - | - | - | - |
| 5-OH | - | - | 12.12 s | - | 12.68 s | - | 12.07 s | - |
| 7-OH | - | - | 10.79 s | - | - | - | - | |
| 2′-OH | - | - | 8.71 s | - | - | - | 8.48 s | - |
| 3′-OH | - | - | 9.51 s | - | - | - | 6.09 s | - |
| 1″ | - | - | - | - | 4.89 d (7.8) | 101.1 | - | - |
| 2″ | - | - | - | - | 3.14 m | 73.3 | - | - |
| 3″ | - | - | - | - | 3.25 m | 76.5 | - | - |
| 4″ | - | - | - | - | 3.12 m | 69.7 | - | - |
| 5″ | - | - | - | - | 3.32 m | 77.1 | - | - |
| 6a″ | - | - | - | - | 3.70 dd (5.0, 11.5) | 60.7 | - | - |
| 6b″ | - | - | - | - | 3.46 m | | - | |
| 2″-OH | - | - | - | - | 5.05 d (5.0) | - | - | - |
| 3″-OH | - | - | - | - | 5.01 overlap | - | - | - |
| 4″-OH | - | - | - | - | 5.02 overlap | - | - | - |
| 6″-OH | - | - | - | - | 4.57 t (5.8, 11.5) | - | - | - |
| 6-OCH₃ | - | - | - | - | 3.79 s (3H) | 61.0 | 3.91 s (3H) | 61.9 |
| 7-OCH₃ | - | - | - | - | 3.94 s (3H) | 56.6 | 3.99 s (3H) | 56.7 |

*—in CDCl₃, **—in DMSO-*d₆.*

**Figure 3.** $^1$H-$^1$H COSY (—) and key HMBC (→) correlations of **2**, **3**, **9**, and **10**.

The absolute configuration at C-2 of compound **3** was determined as 2S based on its CD spectrum (Figure S25, Supplementary Materials), which displayed a positive Cotton effect at 325 nm and a negative one at 283 nm [11,12]. Consequently, compound **3** was elucidated as (2S)-5,7,2′,3′-tetrahydroxyflavanone, an undescribed member of a flavanone group of natural products.

Compound **9** was isolated as yellow crystal. The molecular formula $C_{23}H_{24}O_{11}$ was established on the basis of the positive ion at *m/z* 477.1399 [M + H]$^+$ by HR-ESI-MS. The $^1$H NMR spectrum revealed the presence of five aromatic protons (Table 2). The COSY spectrum showed a spin system comprising four aromatic protons at $\delta_H$ 7.37 (1H, overlap.), 7.27 (1H, d, *J* = 8.2 Hz), 7.35 (1H, overlap.), and 7.09 (1H, t, *J* = 7.5 Hz), characteristic for an *ortho*-substituted B-ring of aglycone (Figure 3). The remaining aromatic signal appeared as a sharp singlet at 6.64 (1H, s) together with chelated hydroxyl group at $\delta_H$ 12.68 suggested a typical penta-substituted aromatic A-ring. The singlet was assigned on C-8 according to HMBC correlation from H-8 to C-9 ($\delta_C$ 149.2) and C-7 ($\delta_C$ 158.3). The chelated hydroxyl group was positioned at C-5 by means of HMBC. In addition, a characteristic isoflavonoid signal for H-2 was appeared at $\delta_H$ 8.44. The isoflavone nature was supported by long-range correlations from H-2 ($\delta_H$ 8.44) to C-4 ($\delta_C$ 180.5), C-9 ($\delta_C$ 149.2), and C-1′ ($\delta_C$ 120.0) in the HMBC spectrum. Furthermore, two methoxyl singlet signals were apparent at $\delta_H$ 3.79 and 3.94, and they were located at C-6 and C-7 due to HMBC correlations between 6-OCH$_3$ and C-6 ($\delta_C$ 128.3), as well as 7-OCH$_3$ and C-7 ($\delta_C$ 158.3). Moreover, a series of COSY cross signals comprising six protons in the range of $\delta_H$ 3.0–4.0, four hydroxy protons $\delta_H$ 4.57–5.05, as well as a doublet at $\delta_H$ 4.89, revealed the presence of a glucose moiety (H-1″ to H-6″) [16]. The HMBC correlation from H-1″ ($\delta_H$ 4.89) to C-2′ ($\delta_C$ 155.1) revealed the sugar moiety was located at C-2′ of aglycone. The coupling constant of anomeric proton *J* = 7.80 Hz indicated that the sugar was *β*-oriented. The $^1$H and $^{13}$C NMR spectroscopic data of aglycone of **9** were comparable with the literature values for the irilin A [17,18]. The only difference was occurred on C-2′, where OH group of irilin A was replaced by glucopyranosyl in **9**. Finally, the structure of compound **9** was elucidated as 5-hydroxy-6,7-dimethoxyisoflavone-2′-O-*β*-D-glucopyranoside, an unprecedented natural product.

Compound **10** was isolated as yellow crystal. HR-ESI-MS showed the [M + H]$^+$ peak at *m/z* 331.0825, corresponding to the molecular formula $C_{17}H_{14}O_7$. $^1$H NMR, $^{13}$C NMR, and HSQC data of compound **10** closely resembled to that of **9**, differing only on the absence of signals corresponding to a sugar moiety and different pattern on aromatic signals of B-ring (Table 2). The COSY correlation of a triplet at $\delta_H$ 6.92 (1H, t, *J* = 7.9 Hz) with two doublets of doublets at $\delta_H$ 7.03 (1H, dd, *J* = 1.3, 7.9 Hz) and 6.71 (1H, dd, *J* = 1.5, 7.8 Hz), and their HMBC correlations clearly indicated *ortho*-dihydroxyl substitution on B-ring. The position of the hydroxyl groups, which were appeared as two singlets in the $^1$H NMR spectrum at $\delta_H$ 8.48 and 6.09, were assigned at C-2′ and C-3′, due to the HMBC correlations (Figure 3). Therefore, the structure of **10** was solved as 5,2′,3′-trihydroxy-6,7-dimethoxyisoflavone, which is an undescribed natural product so far.

Furthermore, the known compounds were readily identified by means of HR-ESI-MS, 1D, and 2D NMR data as well as in comparison with those previously reported in the literature: compound **4** as 5,2′-dihydroxy-6,7-methylenedioxyflavanone [15], **5** as 5,2′,3′-trihydroxy-6,7-methylenedioxyflavanone [15], **6** as 5,2′,3′-trihydroxy -7-methoxy-flavanone [15], **7** as 3,5,3′-trihydroxy-7,2′-dimethoxyflavanone [15], **8** as 5,7-dihydroxy-6,2′-

dimethoxyisoflavone [19], **11** as 3,5,3′-trihydroxy-7,2′-dimethoxy -flavonol [20], and **12** as *β*-sitosterol [2,21] (Figure 1). To the best of our knowledge, the known compound **11** was isolated for the first time from this plant.

### 2.2. Antimicrobial Activity

The newly discovered compounds **1**, **2**, **3**, **9**, and **10** were tested together with the known compound **5**, which is the major component of the roots of this plant [15] for their antifungal and antibacterial activities against three fungi and eight bacterial strains (Table 3) using the agar diffusion method. All tested compounds possessed weak to moderate activity against vancomycin resistant (VRE) *Enterococcus faecalis*. Compounds except **1** and **9** exhibited weak and moderate activities against *Bacillus subtilis* and *Mycobacterium vaccae*, respectively, compared to ciprofloxacin. Compounds **3**, **5**, and **10**, which contain *ortho*-dihydroxyl groups in B-ring at positions 2′ and 3′, were most active against bacterial strains. This supports the evidence that the *ortho* -dihydroxyl structural fragment in B-ring is important for antimicrobial activity [22]. Compound **2**, a new cycloflavan, demonstrated activity against *B. subtilis*, *E. faecalis*, and *M. vaccae*. Interestingly, the new compounds **1** and **9**, which have a glucose unit in their structure, showed selective activity only against *E. faecalis* VRE.

**Table 3.** Antimicrobial activity using agar diffusion method of some isolated compounds from *I. tenuifolia*.

| Test Microorganism | Inhibition Zone of Test Microorganism (mm) | | | | | | |
|---|---|---|---|---|---|---|---|
| | **1** | **2** | **3** | **5** | **9** | **10** | **Standard** |
| | Gram-positive | | | | | | Ciprofloxacin |
| *Staphylococcus aureus* (511 B3) | - | - | - | 15 | - | - | 19 |
| *Bacillus subtilis* (6633 B1) | - | 12 | 12 | 13 | - | 13 | 29 |
| *Staphylococcus aureus* (MRSA 134/94 R9) | - | - | - | 13 | - | - | - |
| *Enterococcus faecalis* (VRE 1528 R10) | 13 | 14 | 17 | 13 | 13 | 13 | 16 |
| | Gram-negative | | | | | | |
| *Escherichia coli* (458 B4) | - | - | - | - | - | - | 32 |
| *Pseudomonas aeruginosa* (SG137 B7) | - | - | - | - | - | - | 25 |
| *Pseudomonas aeruginosa* (K799/61 B9) | - | - | - | 17 | - | - | 35 |
| *Mycobacterium vaccae* (10670 M4) | - | 17 | 23 | 20 | - | 16 | 22 |
| | Fungi | | | | | | Amphotericin B |
| *Sporobolomyces salmonicolor* (549 H4) | - | - | - | - | - | - | 19 |
| *Candida albicans* (C.alb.H8) | - | - | - | 13 | - | 13 | 20 |
| *Penicillium notatum* (JP36 P1) | - | - | - | 16 | - | - | 19 |

VRE—Vancomycin resistant *Enterococci*; MRSA—Methicillin resistant *Staphylococcus aureus*;—showed no activity.

As for the fungi, the compound **5** showed moderate activity against *Penicillium notatum*, and compounds **5** and **10** showed weak activity against *Candida albicans*. It is noteworthy that compound **5**, which contains a methylenedioxy group, in addition to the *ortho*-dihydroxyl groups in B-ring, showed broad activity against eight microorganisms out of eleven. However, no inhibition was observed with the tested compounds against bacterial strains of *Escherichia coli* and *Pseudomonas aeruginosa* (SG137 B7) or against the fungus *Sporobolomyces Salmonicolor*. This is the first report on the antimicrobial activity of the tested compounds.

### 2.3. Antiproliferative and Cytotoxic Activities

Using HUVEC, K-562, THP-1, A549, and HeLa cell lines, the antiproliferative activities and the cytotoxicity of the isolated compounds (**1–12**) along with plant raw extract were evaluated in vitro (Table 4). The plant extract possessed antiproliferative effects against leukemia cell lines and a cytotoxic effect on Hela cells. With the exception of **12**, the

compounds tested in this study were chromane derivatives. Compounds **4–6** and **10** showed inhibition effects against all of the applied cancer cell lines and exhibited potential antiproliferative activities against the THP-1 cell line with $GI_{50}$ values at 16.0, 16.5, 16.9, and 9.1 μM, respectively. Moreover, compound **10** demonstrated the most potent activity ($GI_{50}$ = 7.6 μM) against the K-562, followed by compounds **2** and **3** with $GI_{50}$ value at 31.5 and 32.3 μM. Compound **3**, the tetrahydroxy flavanone, showed selective antiproliferative inhibition effect against the K-562 cells only. These results are in a good agreement with previous studies and supports the evidence that the *ortho*-dihydroxyl structural fragment in B-ring is very important for anticancer activity [7,23–25]. Furthermore, compound **2**, the cycloflavan, exhibited significant inhibitory activities against cell lines HUVEC and THP-1 with a $GI_{50}$ values at 35.2 and 29.2 μM and showed the cytotoxic effect on HeLa cells with $CC_{50}$ value at 42.6 μM among the tested compounds. Besides that, compound **10** showed a similar moderate inhibition effect ($GI_{50}$ = 35.8 μM) on HUVEC cells. All the flavonoids examined showed their low toxicity with $CC_{50}$ values of more than 100 μM on HeLa cells. In cases of compounds **7** and **8** which do not have *ortho*-dihydroxy substitutions on the A and B rings, reduced or no inhibitory effects were found compared to other compounds mentioned above. Compound **11** showed slightly increased activity against K-562 and moreover against THP-1 and A549 cell lines compared to compound **7**. Thus, it supports the relevance of the C-2 and C-3 double bond in a flavonoid structure [23]. In contrast to **10**, compound **9**, which differs in its structure in the presence of a sugar moiety and a dehydroxylation on the B-ring, became completely not effective. Interestingly, compound **1**, which also has a sugar residue in its structure, did not show any activity up to 100 μM against all human cancer cell lines either. Hence, the results are consistent with previous research that flavonoids glycosides were generally not effective against multiple cancer cell lines [23]. Compound **12** showed neither an antiproliferative effect nor a cytotoxicity within the tested range against all applied cell lines.

**Table 4.** Antiproliferative and cytotoxic activity of the plant extract and isolated compounds from *I. tenuifolia*.

| Compound | Antiproliferative Effect, $GI_{50}$ (μM) (CI 95%) | | | | Cytotoxicity $CC_{50}$ (μM) (CI 95%) |
|---|---|---|---|---|---|
| | HUVEC | K-562 | THP-1 | A549 | HeLa |
| **1** | >100 | >100 | >100 | >100 | >100 |
| **2** | 35.2 (35.0–35.4) | 31.5 (31.2–31.8) | 29.2 (29.1–29.3) | >100 | 42.6 (41.8–43.4) |
| **3** | >100 | 32.3 (32.1–32.5) | >100 | >100 | >100 |
| **4** | 73.3 (72.8–73.8) | 48.7 (46.8–50.6) | 16.0 (15.9–16.1) | 81.0 (80.7–81.3) | >100 |
| **5** | 69.0 (68.5–69.5) | 44.3 (41.6–47.0) | 16.5 (16.4–16.6) | >100 | >100 |
| **6** | 68.2 (67.6–68.8) | 56.0 (54.3–57.7) | 16.9 (16.8–17.0) | 70.9 (69.7–72.1) | >100 |
| **7** | >100 | 97.6 (95.8–99.4) | >100 | >100 | >100 |
| **8** | >100 | >100 | >100 | >100 | >100 |
| **9** | >100 | >100 | >100 | >100 | >100 |
| **10** | 35.8 (35.4–36.2) | 7.6 (7.5–7.7) | 9.1 (9.07–9.13) | 98.8 (97.7–99.9) | >100 |
| **11** | >100 | 71.5 (71.1–71.9) | 50.6 (49.0–52.2) | 67.0 (66.6–67.4) | >100 |
| **12** | >100 | >100 | >100 | >100 | >100 |
| Imatinib | 22.1 (20.9–23.2) | 0.2 (0.20–0.21) | n.d | n.d | 78.6 (77.3–80.0) |
| Doxorubicin | 0.13 (0.10–0.16) | 0.13 (0.12–0.14) | n.d | n.d | 0.48 (0.46–0.49) |
| Plant extract (μg/mL) | ≥50 | 47.2 (±1.8) | 31.6 (±6.3) | >50 | 40.0 (±4.9) |

The $GI_{50}$ and $CC_{50}$ values with 95% confidence intervals (CI 95%): 1–10 (very strong); 11–20 (strong); 21–50 (moderate); 51–100 (weak), and >100 (ineffective); n.d—not determined.

## 3. Materials and Methods

### 3.1. General Experimental Procedures

Solvents and reagents were purchased from Sigma-Aldrich, Deisenhofen, Germany and Qingdao Marine Chemical, China. The optical data were measured using a digital JASCO P-2000 polarimeter (Jasco, Pfungstadt, Germany). The CD spectrum was recorded on a JASCO J810 spectropolarimeter (Jasco, Pfungstadt, Germany). Ultraviolet-visible (UV-Vis) data were extracted from diode array detector (DAD) data obtained during high performance liquid chromatography-electrospray ionization-high resolution mass spectrometry (HPLC-ESI-HRMS) experiments.

NMR spectra were recorded at 298 K on 500 MHz Bruker Avance III HD spectrometer (Bruker Biospin, Rheinstetten, Germany), equipped with cryoplatforms and TCI cryoprobes (5 mm). Spectrometer control and data processing were accomplished using Bruker Topspin ver.3.2 (Bruker Biospin, Rheinstetten, Germany), and standard pulse programs were used. NMR signals were referenced to the respective solvent signals at $\delta_H$ 2.50 and $\delta_C$ 39.53 for hexadeuterodimethyl sulfoxide DMSO-$d_6$ and $\delta_H$ 7.26 and $\delta_C$ 77.06 for deuterochloroform CDCl$_3$. HPLC-ESI-HRMS spectra were recorded on an Agilent Infinity 1260, consisting of a combined degasser and quaternary pump, column oven, autosampler, and DAD. The DAD was coupled to a Bruker Compact quadrupole time-of-flight (QTOF) mass spectrometer (Bruker Daltonics, Bremen, Germany). Both devices were controlled by Bruker Compass ver.1.9 (Bruker Daltonics, Bremen, Germany). For HPLC separation, an Agilent Zorbax C-18 SB column (3.5 µm, 4.6 × 150 mm i.d.) was used. The mass spectrometer was operated, depending on the analyte, either in positive or negative ionization mode, employing an electrospray ionization (ESI) source. The standard settings for small molecule analysis, as provided with Bruker Compass, were used. Column chromatographic separations were performed on silica gel (200–300 mesh, Merck, Darmstadt, Germany and Qingdao Marine Chemical, China) and Sephadex LH-20 (Pharmacia Fine Chemical, Uppsala, Sweden). Thin-layer chromatography (TLC) was performed on pre-coated TLC plates with silica gel 60 F$_{254}$ (Merck, Darmstadt, Germany). Spots were detected under UV absorption ($\lambda_{max}$ 254 and 364 nm) by spraying with 1% methanolic diphenylboric acid-$\beta$-ethylaminoester, 5% ethanolic polyethylene glycol or under visible light by spraying with 5% ethanolic sulfuric acid and 1% acidified methanolic vanillin.

### 3.2. Plant Material

Rhizomes and roots of *I. tenuifolia* were collected in September 2016 from Khurmen Sum of South Gobi province of Mongolia. It was identified by Urgamal Magsar, a botanist of the Institute of General and Experimental Biology, Mongolian Academy of Sciences, where voucher specimens (It 0916) of the plant have been deposited.

### 3.3. Extraction and Isolation

The air dried and powdered plant material (5.0 kg) was extracted three times with 95% ethanol (crude extract I) and three more times with 50% ethanol (crude extract II). The extracts were evaporated under vacuum to yield a brown residue. Crude extract I (700 g) was fractionated by column chromatography on a silica gel column, eluted with dichloromethane (CH$_2$Cl$_2$) and mixtures of CH$_2$Cl$_2$ and methanol (CH$_2$Cl$_2$-MeOH) (50:1, 30:1, 10:1, 5:1, 1:1, *v/v*) with increasing polarity. Eluates were pooled into seven fractions (A–G) on the basis of TLC analysis. Fractions A and B were subjected to column chromatography on silica gel eluted with a chloroform (CHCl$_3$) and the mixture of CHCl$_3$-MeOH (70:1, 50:1, 30:1, 10:1, 5:1, 1:1, *v/v*) with increasing polarity to give subfractions A.1–A.7 and B.1–B.6, respectively. Subfraction A.2 was further purified on silica gel column eluting with petroleum ether and ethyl acetate (pet.ether-EtOAc) (50:1, 30:1, 10:1, 5:1, 1:1, *v/v*) followed by Sephadex LH-20 eluting with CHCl$_3$-MeOH (1:1, *v/v*) to yield compounds **4** (20.4 mg), **7** (39.9 mg), **8** (328.8 mg), **10** (85.9 mg), **11** (29.3 mg), and **12** (151.8 mg). Further subfraction B.5 was subjected to silica gel column chromatography eluting with CHCl$_3$-MeOH (70:1, 50:1, 30:1, 10:1, 5:1, 3:1, 1:1, *v/v*) followed by Sephadex

LH-20 with $CHCl_3$-MeOH (1:1, *v/v*) to yield compounds **3** (105.6 mg), **5** (88.2 mg), and **6** (19.4 mg). These compounds were recrystallized from $CHCl_3$-MeOH (1:1, *v/v*). Fraction D was separated on silica gel column chromatography using $CHCl_3$-MeOH (50:1, 30:1, 10:1, 5:1, 1:1, *v/v*) as an eluent to give eight subfractions (D.1–D.8). Compound **9** (11.5 mg) was obtained in pure form by recrystallisation from $CHCl_3$-MeOH (1:1 *v/v*) from subfraction D.4. Subfraction D.5 was further subjected on silica gel eluting with $CHCl_3$-MeOH (10:1, *v/v*) and then purified on silica gel with pet.ether-EtOAc (5:1, 3:1, 1:1, 1:3, 1:5, *v/v*) to afford compound **1** (6.9 mg). Crude extract II (52 g) was fractionated by column chromatography on silica gel eluted with $CHCl_3$ and $CHCl_3$-MeOH ($CHCl_3$, 50:1, 30:1, 10:1, 5:1, 3:1, 1:1, MeOH, *v/v*) and pooled into eight fractions (A–H). Fraction A was subjected to silica gel column eluted with a gradient of pet.ether-EtOAc (50:1, 30:1, 10:1, 5:1, 1:1, *v/v*) to yield compound **2** (11.0 mg) and which was further recrystallized from $CHCl_3$-MeOH (1:1, *v/v*).

Moniristenulide (**1**): white powder, $[\alpha]_D^{25}$ + 44 (*c* = 0.18, DMSO), CD (*c* = 0.22, MeOH) 305 nm ($\Delta\varepsilon$ + 1.25) and 287 nm ($\Delta\varepsilon$ − 3.96), UV ($CH_3CN/H_2O$): $\lambda_{max}$ 206, 228, 282, 326 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) and $^{13}$C NMR (125 MHz, DMSO-$d_6$) data, see Table 1; HR-ESI-MS: *m/z* 453.1409 [M + H]$^+$ (calcd. for $C_{21}H_{25}O_{11}$, 453.1397).

5-Methoxy-6,7-methylenedioxy-4-*O*-2′-cycloflavan (**2**): colorless crystal, $[\alpha]_D^{25}$ + 317 (*c* = 0.67, DMSO), UV ($CH_3CN/H_2O$): $\lambda_{max}$ 196, 206, 286 nm; $^1$H NMR (500 MHz, $CDCl_3$) and $^{13}$C NMR (125 MHz, $CDCl_3$) data, see Table 2; HR-ESI-MS: *m/z* 299.0919 [M + H]$^+$ (calcd. for $C_{17}H_{15}O_5$, 299.0920).

(2S)-5,7,2′,3′-Tetrahydroxyflavanone (**3**): yellow powder; $[\alpha]_D^{25}$ + 10 (*c* = 0.67, DMSO), CD (*c* = 0.69, MeOH) 325 nm ($\Delta\varepsilon$ + 2.40) and 283 nm ($\Delta\varepsilon$ − 11.70), UV ($CH_3CN/H_2O$): $\lambda_{max}$ 202, 288 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) and $^{13}$C NMR (125 MHz, DMSO-$d_6$) data, see Table 2; HR-ESI-MS: *m/z* 289.0714 [M + H]$^+$ (calcd. for $C_{15}H_{13}O_6$, 289.0712).

5,2′-Dihydroxy-6,7-methylenedioxyflavanone (**4**): yellow powder, UV ($CH_3CN/H_2O$): $\lambda_{max}$ 206, 228, 280 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) $\delta_H$ 11.86 (1H, s, 5-OH), 9.89 (1H, s, 2′-OH), 7.43 (1H, d, *J* = 7.5 Hz, H-6′), 7.19 (1H, t, *J* = 7.5 Hz, H-4′), 6.88 (1H, overlap, H-5′), 6.86 (1H, overlap, H-3′), 6.31 (1H, s, H-8), 6.06 (2H, d, *J* = 6.9 Hz, -CH$_2$-), 5.72 (1H, dd, *J* = 2.8, 13.1 Hz, H-2), 3.26 (1H, dd, *J* = 13.4, 17.1 Hz, H-3a), 2.74 (1H, dd, *J* = 2.9, 17.1 Hz, H-3b). $^{13}$C NMR (125 MHz, DMSO-$d_6$) $\delta_C$ 74.6 (C-2), 41.2 (C-3), 197.9 (C-4), 143.1 (C-5), 127.4 (C-6), 155.8 (C-7), 90.4 (C-8), 159.4 (C-9), 103.6 (C-10), 124.5 (C-1′), 154.4 (C-2′), 115.6 (C-3′), 129.6 (C-4′), 119.2 (C-5′), 127.1 (C-6′), 102.5 (-CH2-). HR-ESI-MS: *m/z* 301.0722 [M + H]$^+$ (calcd. for $C_{16}H_{13}O_6$, 301.0712).

5,2′,3′-Trihydroxy-6,7-methylenedioxyflavanone (**5**): yellow crystal, $[\alpha]_D^{25}$ + 9 (*c* = 0.8, DMSO), UV ($CH_3CN/H_2O$): $\lambda_{max}$ 206, 244, 284 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) $\delta_H$ 11.88 (1H, s, 5-OH), 9.52 (1H, s, 3′-OH), 8.74 (1H, s, 2′-OH), 6.90 (1H, d, *J* = 7.8 Hz, H-6′), 6.80 (1H, dd, *J* = 1.2, 7.8 Hz, H-4′), 6.69 (1H, t, *J* = 7.8 Hz, H-5′), 6.30 (1H, s, H-8), 6.07 (2H, d, *J* = 6.6 Hz, -CH2-), 5.73 (1H, dd, *J* = 2.8, 13.2 Hz, H-2), 3.24 (1H, dd, *J* = 13.3, 17.2 Hz, H-3a), 2.73 (1H, dd, *J* = 2.9, 17.2 Hz, H-3b). $^{13}$C NMR (125 MHz, DMSO-$d_6$) $\delta_C$ 74.6 (C-2), 41.2 (C-3), 197.9 (C-4), 143.1 (C-5), 127.3 (C-6), 155.7 (C-7), 90.4 (C-8), 159.4 (C-9), 103.6 (C-10), 125.2 (C-1′), 142.6 (C-2′), 145.2 (C-3′), 115.3 (C-4′), 119.0 (C-5′), 117.1 (C-6′), 102.4 (-CH$_2$-). HR-ESI-MS: *m/z* 317.0666 [M + H]$^+$ (calcd. for $C_{16}H_{13}O_7$, 317.0661).

5,2′,3′-Trihydroxy-7-methoxyflavanone (**6**): yellow crystal; UV ($CH_3CN/H_2O$): $\lambda_{max}$ 206, 226, 286 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) $\delta_H$ 12.09 (1H, s, 5-OH), 9.56 (1H, s, 3′-OH), 8.74 (1H, s, 2′-OH), 6.89 (1H, d, *J* = 7.7 Hz, H-6′), 6.79 (1H, d, *J* = 7.7 Hz, H-4′), 6.69 (1H, t, *J* = 7.8 Hz, H-5′), 6.11 (1H, d, *J* = 2.0 Hz, H-8), 6.08 (1H, d, *J* = 2.0 Hz, H-6), 5.73 (1H, dd, *J* = 2.8, 12.9 Hz, H-2), 3.79 (3H, s, 7-OCH$_3$), 3.23 (1H, dd, *J* = 12.9, 17.2 Hz, H-3a), 2.73 (1H, dd, *J* = 3.0, 17.2 Hz, H-3b). $^{13}$C NMR (125 MHz, DMSO-$d_6$) $\delta_C$ 74.2 (C-2), 41.2 (C-3), 196.9 (C-4), 163.2 (C-5), 94.7 (C-6), 167.4 (C-7), 93.8 (C-8), 159.4 (C-9), 102.6 (C-10), 125.4 (C-1′), 143.1 (C-2′), 145.2 (C-3′), 115.2 (C-4′), 119.0 (C-5′), 117.1 (C-6′), 55.9 (7-OCH$_3$). HR-ESI-MS: *m/z* 303.0877 [M + H]$^+$ (calcd. for $C_{16}H_{15}O_6$, 303.0868).

3,5,3′-Trihydroxy-7,2′-dimethoxyflavanone (**7**): white powder; UV ($CH_3CN/H_2O$): $\lambda_{max}$ 206, 226, 282 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) $\delta_H$ 11.88 (1H, s, 5-OH), 9.49 (1H, s, 3′-OH), 6.99 (1H, overlap, H-6′), 6.97 (1H, overlap, H-5′), 6.90 (1H, dd, *J* = 3.1, 6.3 Hz, H-4′),

6.13 (1H, d, $J$ = 2.2 Hz, H-6), 6.08 (1H, d, $J$ = 2.2 Hz, H-8), 5.94 (1H, d, $J$ = 6.1 Hz, 3-OH), 5.46 (1H, d, $J$ = 11.6 Hz, H-2), 4.77 (1H, dd, $J$ = 6.1, 11.5 Hz, H-3), 3.78 (3H, s, 7-OCH$_3$), 3.74 (3H, s, 2′-OCH$_3$). $^{13}$C NMR (125 MHz, DMSO-$d_6$) $\delta_C$ 77.7 (C-2), 70.7 (C-3), 198.4 (C-4), 163.1 (C-5), 94.9 (C-6), 167.6 (C-7), 93.8 (C-8), 162.5 (C-9), 101.4 (C-10), 130.4 (C-1′), 146.7 (C-2′), 150.2 (C-3′), 117.2 (C-4′), 123.9 (C-5′), 118.6 (C-6′), 60.5 (7-OCH$_3$), 55.9 (2′-OCH$_3$). HR-ESI-MS: $m/z$ 333.0982 [M + H]$^+$ (calcd. for C$_{17}$H$_{17}$O$_7$, 333.0974).

5,7-Dihydroxy-6,2′-dimethoxyisoflavone (**8**): yellow crystal, UV (CH$_3$CN/H$_2$O): $\lambda_{max}$ 196, 226, 262 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) $\delta_H$ 12.94 (1H, s, 5-OH), 10.78 (1H, s, 7-OH), 8.24 (1H, s, H-2), 7.40 (1H, dd, $J$ = 1.4, 7.5 Hz, H-4′), 7.24 (1H, dd, $J$ = 1.4, 7.5 Hz, H-6′), 7.09 (1H, d, $J$ = 8.3 Hz, H-3′), 7.00 (1H, t, $J$ = 7.5 Hz, H-5′), 6.52 (1H, s, H-8), 3.75 (3H, s, 6-OCH$_3$), 3.73 (3H, s, 2′-OCH$_3$). $^{13}$C NMR (125 MHz, DMSO-$d_6$) $\delta_C$ 155.3 (C-2), 119.8 (C-3), 180.1 (C-4), 152.8 (C-5), 131.5 (C-6), 157.5 (C-7), 94.0 (C-8), 153.1 (C-9), 104.7 (C-10), 120.2 (C-1′), 157.5 (C-2′), 111.3 (C-3′), 129.9 (C-4′), 120.0 (C-5′), 131.6 (C-6′), 59.9 (6-OCH$_3$), 55.6 (7-OCH$_3$). HR-ESI-MS: $m/z$ 315.0888 [M + H]$^+$ (calcd. for C$_{17}$H$_{15}$O$_6$, 315.0868).

5-Hydroxy-6,7-dimethoxyisoflavone-2′-*O*-$\beta$-D-glucopyranoside (**9**): yellow crystal, UV (CH$_3$CN/H$_2$O): $\lambda_{max}$ 206, 216, 262, 336 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) and $^{13}$C NMR (125 MHz, DMSO-$d_6$) data, see Table 2; HR-ESI-MS: $m/z$ 477.1399 [M + H]$^+$ (calcd. for C$_{23}$H$_{25}$O$_{11}$, 477.1397)

5,2′,3′-Trihydroxy-6,7-dimethoxyisoflavone (**10**): yellow powder, UV (CH$_3$CN/H$_2$O): $\lambda_{max}$ 206, 222, 258, 338 nm; $^1$H NMR (500 MHz, CDCl$_3$) and $^{13}$C NMR (125 MHz, CDCl$_3$) data, see Table 2; HR-ESI-MS: $m/z$ 331.0825 [M + H]$^+$ (calcd. for C$_{17}$H$_{15}$O$_7$, 331.0818).

3,5,3′-Trihydroxy-7,2′-dimethoxyflavonol (Irisflavone D) (**11**): yellow amorphous powder, UV (CH$_3$CN/H$_2$O): $\lambda_{max}$ 198, 256, 302, 344 nm; $^1$H NMR (500 MHz, DMSO-$d_6$) $\delta_H$ 12.48 (1H, s, 5-OH), 9.70 (1H, s, 3′-OH), 9.14 (1H, s, 3-OH), 7.03 (1H, overlap, H-5′), 7.02 (1H, overlap, H-4′), 6.93 (1H, t, $J$ = 4.8 Hz, H-6′), 6.61 (1H, d, $J$ = 2.1 Hz, H-8), 6.38 (1H, d, $J$ = 2.1 Hz, H-6), 3.84 (3H, s, 7-OCH$_3$), 3.77 (3H, s, 2′-OCH$_3$). $^{13}$C NMR (125 MHz, DMSO-$d_6$) $\delta_C$: 148.3 (C-2), 137.3 (C-3), 176.5 (C-4), 160.7 (C-5), 97.5 (C-6), 165.0 (C-7), 92.0 (C-8), 156.7 (C-9), 104.6 (C-10), 124.9 (C-1′), 145.9 (C-2′), 150.5 (C-3′), 123.7 (C-4′), 118.8 (C-5′), 120.9 (C-6′), 60.3 (2′-OCH$_3$), 56.1 (7-OCH$_3$). HR-ESI-MS: $m/z$ 331.0835 [M + H]$^+$ (calcd. for C$_{17}$H$_{15}$O$_7$, 331.0817).

$\beta$-Sitosterol (**12**): white powder, $^1$H NMR (500 MHz, CDCl$_3$) $\delta_H$ 5.35 (1H, d, $J$ = 5.3 Hz, H-5), 3.52 (1H, m, H-3), 1.01 (3H, s, H-29), 0.92 (3H, d, $J$ = 6.62 Hz, H-19), 0.84 (3H, t, $J$ = 7.5 Hz, H-24), 0.82 (3H, d, $J$ = 1.8 Hz, H-26), 0.80 (3H, d, $J$ = 7.0 Hz, H-27), 0.68 (3H, s, H-28). $^{13}$C NMR (CDCl$_3$, 125 MHz) $\delta_C$ 37.4 (C-1), 31.8 (C-2), 71.9 (C-3), 42.5 (C-4), 140.9 (C-5), 121.9 (C-8), 29.8 (C-7), 32.0 (C-8), 50.3 (C-9), 36.6 (C-10), 21.2 (C-11), 39.9 (C-12), 42.4 (C-13), 56.9 (C-14), 25.5 (C-15), 28.4 (C-16), 56.2 (C-17), 36.3 (C-18), 19.2 (C-19), 34.1 (C-20), 26.2 (C-21), 45.9 (C-22), 23.2 (C-23), 12.1 (C-24), 29.3 (C-25), 19.9 (C-26), 19.5 (C-27), 18.9 (C-28), 12.0 (C-29).

### 3.4. Antimicrobial Activity Assay

Compounds **1**, **2**, **3**, **5**, **9**, and **10** were tested for their antimicrobial activities against *S. aureus* (JMRC:STI 10760), *B. subtilis* (JMRC:STI 10880), *S. aureus* MRSA (JMRC: ST 33793) *E. faecalis* VRE (JMRC: ST 33700), *E. coli* (JMRC:ST 33699), *P. aeruginosa* (JMRC:ST 33771), *P. aeruginosa* (JMRC:ST 33772), *M. vaccae* (JMRC:STI 10670), *S. salmonicolor* (JMRC:ST 35974), *C. albicans* (JMRC:STI 25000), and *P. notatum* (JMRC:STI 50164)) using agar diffusion assay as previously published [26]. Strains were obtained from the Jena Microbial Resource Collection (JMRC). The bacteria were cultivated on standard I nutrient agar in Petri dishes at 37 °C. Antifungal bioassays were conducted at 30 °C using the basidiomycetous yeast *S. salmonicolor* and the filamentous ascomycete *P. notatum*, which were cultivated on malt agar, and the ascomycetous yeast *C. albicans*, which was cultivated on yeast morphology agar. After inoculation of the test organisms, a disc (9 mm in diameter) was removed from the center of the Petri dish and 50 μL of the test solution (1 mg/mL in DMSO) was added to the cavity. After 18 h of incubation, the inhibiting areola were measured and documented as diameters in mm. Ciprofloxacin (5 μg/mL in deionized water) and amphotericin B

(10 µg/mL in DMSO/MeOH 1:1) were used as reference substances against bacterial and fungal strains, respectively.

### 3.5. Antiproliferation and Cytotoxicity Assays

Compounds (**1**–**12**) were assayed against human umbilical vein endothelial cells (HUVEC), human chronic myeloid leukemia cells (K-562), human acute monocytic leukemia cells (THP-1), and human lung carcinoma cells (A549) for their antiproliferative effects and against human cervix carcinoma cells (HeLa) for their cytotoxic effect. The antiproliperative and cytotoxic effects were tested via CellTiter-Blue and methylene blue assay as previously described [27]. In this assay, K-562 (DSM ACC 10), THP-1 (DSM ACC 16), and HeLa (DSM ACC 57) were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Cambrex 12-167F) while HUVEC (ATCC CRL-1730) and A549 (DSM ACC 107) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Cambrex 12-614F). Cells that were grown in the appropriate cell culture medium were supplemented with 10 mL/L ultraglutamine 1 (Cambrex 17-605E/U1), 550 µL/L (50 mg/mL) gentamicin sulfate (Cambrex 17-518Z), and 10% heat inactivated fetal bovine serum (GIBCO Life Technologies 10270-106) at 37 °C. The tested compounds were dissolved in DMSO, and the cells were seeded in 96-well plates at a density of $1 \times 10^4$ cells/well. As for the antiproliferative effect of the compounds, the cells were incubated for 72 h, and $GI_{50}$ values were evaluated to be defined as the concentration causing 50% inhibition of proliferation compared to the untreated control. With regard to the cytotoxic assay, HeLa cells were pre-incubated for 48 h without the test compounds. Then, the cells were exposed with different concentrations of compounds and incubated for 72 h. After that, the adherent HeLa cells were fixed by glutaraldehyde and stained with a 0.05% solutions of methylene blue (SERVA 29198) for 15 min. $CC_{50}$ was evaluated to be defined as the concentration required for the death of 50% of the cell monolayer as compared to control groups. Under our experimental conditions, the optical density measured from the CellTiter-Blue reagent and methylene blue assay is proportional to the number of viable cells. In this experiment, absorbances were measured at 570 nm against the reference wavelength of 600 nm (CellTiter-Blue assay) and at 660 nm (methylene blue assay). Doxorubicin (Adriamycin®) and imatinib (Gleevec®) were used as positive controls for HUVEC, K-562, and HeLa cells. A repeat determination has been conducted in all experiments, and four replicates were assayed. The calculations of the different values of $GI_{50}$ and $CC_{50}$ were performed with software Magellan version 3.00 (Tecan Trading AG, Maennedorf, Switzerland).

### 4. Conclusions

The chemical investigation of the underground parts of *I. tenuifolia* afforded in the isolation of five unprecedented chromane derivatives (**1**–**3**, **9**, **10**) includes an unusual macrolide termed moniristenulide (**1**), together with seven known compounds (**4**–**8**, **11**–**12**). Notably, eight out of nine isolated flavonoids have a rare 2′,3′-disubstituted configuration on the B-ring, out of which the compounds bearing *ortho*-dihydroxyl groups in B-ring, namely **3**, **5,** and **10,** showed the broadest antimicrobial activity. On top of that, the molecules with methoxy or methylenedioxy substitution on the A-ring together with *ortho*-hydroxyl groups on the B-ring showed promising antiproliferative activities against leukemia cell lines in combination with low cytotoxicity, as shown for compounds **4**–**6** and **10**.

## References

1. Iwashina, T.; Mizuno, T. Flavonoids and xanthones from the genus *Iris*: Phytochemistry, relationships with flower colors and taxonomy, and activities and function. *Nat. Prod. Commun.* **2020**, *15*, 1–35. [CrossRef]
2. Choudhary, M.I.; Hareem, S.; Siddiqui, H.; Anjum, S.; Ali, S.; Atta-ur-Rahman; Zaidi, M.I. A benzil and isoflavone from *Iris tenuifolia*. *Phytochemistry* **2008**, *69*, 1880–1885. [CrossRef]
3. Ibrahim, S.R.M.; Mohamed, G.A.; Al-Musayeib, N.M. New constituents from the rhizomes of Egyptian *Iris germanica* L. *Molecules* **2012**, *17*, 2587–2598. [CrossRef] [PubMed]
4. Wang, H.; Cui, Y.; Zhao, C. Flavonoids of the genus *Iris* (Iridaceae). *Mini Rev. Med. Chem.* **2010**, *10*, 643–661. [CrossRef]
5. Singab, A.N.B.; Ayoub, I.M.; El-Shazly, M.; Korinek, M.; Wu, T.Y.; Cheng, Y.-B.; Chang, F.R.; Wu, Y.C. Shedding the light on Iridaceae: Ethnobotany, phytochemistry and biological activity. *Ind. Crop. Prod.* **2016**, *92*, 308–335. [CrossRef]
6. Alam, A. Pharmacology and phytochemistry of isoflavonoids from *Iris* species. *J. Pharmacol. Clin. Res.* **2017**, *3*, 1–6. [CrossRef]
7. Cui, Y.M.; Wang, H.; Liu, Q.R.; Han, M.; Lu, Y.; Zhao, C.Q. Flavans from *Iris tenuifolia* and their effects on *β*-amyloid aggregation and neural stem cells proliferation in vitro. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4400–4403. [CrossRef]
8. Urgamal, M.; Oyuntsetseg, B.; Nyambayar, D.; Dulamsuren, C. *Vascular plants in Biodiversity of Mongolia: A Checklist of Plants, Fungus and Microorganisms*; Mongolica Publishing: Ulaanbaatar, Mongolia, 2019.
9. Urgamal, M.; Gundegmaa, V.; Baasanmunkh, S.; Oyuntsetseg, B.; Darikhand, D.; Munkh-Erdene, T. Additions to the vascular flora of Mongolia—IV. *Proc. Mong. Acad. Sci.* **2019**, *59*, 41–53.
10. Ligaa, U.; Davaasuren, B.; Ninjil, N. *Medicinal Plants of Mongolia Used in Western and Eastern Medicine*; JKC Printing: Ulaanbaatar, Mongolia, 2005.
11. Slade, D.; Ferreira, D.; Marais, J.P.J. Circular dichroism, a powerful tool for the assessment of absolute configuration of flavonoids. *Phytochemistry* **2005**, *66*, 2177–2215. [CrossRef] [PubMed]
12. Feng, W.; Hao, Z.; Li, M. Isolation and structure identification of flavonoids. *Flavonoids Biosynth. Hum. Health* **2017**, *2*, 18–43.
13. Peng, W.; Yang, C.; Zhan, R.; Chen, Y. Two new flavans from the trunk and leaves of *Horsfieldia glabra*. *Nat. Prod. Res.* **2016**, *30*, 2350–2355. [CrossRef]
14. Yang, X.; Zhang, W.; Ying, X.; Stien, D. New flavonoids from *Portulaca oleracea* L. and their activities. *Fitoterapia* **2018**, *127*, 257–262. [CrossRef] [PubMed]
15. Kojima, K.; Gombosurengyin, P.; Ondognyi, P.; Begzsurengyin, D.; Zevgeegyin, O.; Hatano, K.; Ogihara, Y. Flavanones from *Iris tenuifolia*. *Phytochemistry* **1997**, *44*, 711–714. [CrossRef]
16. Al-Saleem, M.S.M.; Al-Wahaib, L.H.; Abdel-Mageed, W.M.; Gouda, Y.G.; Sayed, H.M. Antioxidant flavonoids from *Alhagi maurorum* with hepatoprotective effect. *Pharmacogn. Mag.* **2019**, *15*, 592–599.
17. Hanawa, F.; Tahara, S.; Mizutani, J. Isoflavonoids produced by *Iris Pseudacorus* leaves treated with cupric chloride. *Phytochemistry* **1991**, *30*, 157–163. [CrossRef]
18. Bergeron, C.; Marston, A.; Hakizamungu, E.; Hostettmann, K. Antifungal constituents of *Chenopodium procerum*. *Pharm. Biol.* **1995**, *33*, 115–119. [CrossRef]
19. Shawl, A.S.; Vishwapaul; Zaman, A.; Kalla, A.K. Isoflavones of *Iris spuria*. *Phytochemistry* **1984**, *23*, 2405–2406. [CrossRef]
20. Choudhary, M.I.; Nur-e-Alam, M.; Baig, I.; Akhtar, F.; Khan, A.M.; Ndögnii, P.Ö.; Badarchiin, T.; Purevsuren, G.; Nahar, N.; Atta-ur-Rahman. Four new flavones and a new isoflavone from *Iris bungei*. *J. Nat. Prod.* **2001**, *64*, 857–860. [CrossRef]
21. Vitus Nyigo, A.; Peter, X.; Abiki, F.M.; Alebo, H.M.M.; Degela, R.H.M.; Gerda, F. Isolation and identification of euphol and β-sitosterol from the dichloromethane extracts of *Synadenium glaucescens*. *J. Phytopharm.* **2016**, *5*, 100–104. [CrossRef]
22. Farhadi, F.; Khameneh, B.; Iranshahi, M.; Iranshahy, M. Antibacterial activity of flavonoids and their structure–activity relationship: An update review. *Phyther. Res.* **2019**, *33*, 13–40. [CrossRef] [PubMed]

23. Kawaii, S.; Tomono, Y.; Katase, E.; Ogawa, K.; Yano, M. Antiproliferative activity of flavonoids on several cancer cell lines. *Biosci. Biotechnol. Biochem.* **1999**, *63*, 896–899. [CrossRef]
24. Kawaii, S.; Ishikawa, Y.; Yoshizawa, Y. Relationship between the structure of methoxylated and hydroxylated flavones and their antiproliferative activity in HL60 cells. *Anticancer Res.* **2018**, *38*, 5679–5684. [CrossRef] [PubMed]
25. Grigalius, I.; Petrikaite, V. Relationship between antioxidant and anticancer activity of trihydroxyflavones. *Molecules* **2017**, *22*, 2169. [CrossRef] [PubMed]
26. Krieg, R.; Jortzik, E.; Goetz, A.A.; Blandin, S.; Wittlin, S.; Elhabiri, M.; Rahbari, M.; Nuryyeva, S.; Voigt, K.; Dahse, H.M.; et al. Arylmethylamino steroids as antiparasitic agents. *Nat. Commun.* **2017**, *8*, 14478. [CrossRef] [PubMed]
27. Krauth, F.; Dahse, H.M.; Rüttinger, H.H.; Frohberg, P. Synthesis and characterization of novel 1,2,4-triazine derivatives with antiproliferative activity. *Bioorganic Med. Chem.* **2010**, *18*, 1816–1821. [CrossRef] [PubMed]